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Few cases of malignant rhabdoid tumour (MRT) of the liver are reported in literature and always in paediatric patients. We report
the ﬁrst two cases of young adults submitted to hepatic resection for MRT of the liver. A major liver resection was performed
in both cases. The histology showed round or fusiform, loosely cohesive cells. The cytoplasm contained abundant eosinophilic
inclusions, which caused the nuclei to be located in eccentric locations, giving the characteristic rhabdoid appearance. The
immunohistochemicalstudywasperformed,andcharacteristiclackofnuclearINI1proteinexpressionwasfound.Inacasesurgery
was associated to chemoradiotherapy. One patient died at 48 months followup for tumour recurrence. The other is still alive at
25 months followup. MRTs are rare tumours of pediatric age with poor prognosis. Hypothetical less malignant behaviour in the
young adults could be supposed. Therefore an aggressive surgical and oncological treatment seems justiﬁed.
Copyright © 2009 Ettore Marzano et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Malignant rhabdoid tumours (MRTs) are highly aggressive
tumours which usually presented in the central nervous
system, in the kidneys and soft tissues of children. They were
ﬁrstly described in 1978 as an aggressive variant of Wilms’
tumour [1]. MRT has now been accepted as a distinctive
clinicopathological entity [2]. Since then identical tumours
have been described in a variety of extra-renal organs. The
ﬁrst evidence in literature of a liver tumour with rhabdoid
features was in 1982 by Gonzalez-Crussi et al. [3]. Until
now few cases are reported in literature [4] and always in
paediatric patients.
Wereporttheﬁrsttwocasesofyoungadultssubmittedto
hepatic resection for MRT of the liver. The histological and
immunohistochemical ﬁndings, the surgical treatment, and
the clinical outcome are described.
2.CaseReport
Case 1. A 27-year-old male, in a good overall health, was
admitted at the Emergency Unit for acute epigastric pain
since 48 hours. The clinical examination of the abdomen
found a mass at the palpation of the epigastric region. There
was no weight loss, jaundice, diarrhoea, or vomiting. Trans-
abdominal ultrasound revealed a large heterogeneous mass
with intratumoral arterial vascularization, which occupied
the left liver (15 × 7cm) and the presence of peritoneal
liquid in the Douglas space. The injection of contrast agent
(Sonovue) showed a precocious hypervascularisation of the
lesion whit hypoechogenic spots and late wash-out. No
alterations of biological examinations and tumoral markers
were revealed: alpha fetoprotein = 1.3ng/mL (Normal <5),
CA 19 − 9 = 15.2U/mL (Normal <37). The CT-scan
and the Magnetic Resonance Imaging (MRI) conﬁrmed the
ultrasound report and moreover showed a nodule of 1.5cm
on the segment VIII (Figures 1(a) and 1(b)). The signal and
the vascular kinetic were in favour of a ﬁbrolamellar hepa-
tocarcinoma or of a cholangiocarcinome. The preoperative
biopsies were inconclusive. A left hepatectomy (segments II-
III-IV) with atypical resection of the lesion on the segment
VIII was performed, preserving middle and right hepatic
vein. No postoperative complication was observed. The
patient was discharged at day 7. A simple surveillance was2 HPB Surgery
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Figure 1: CT-scan (a) and the Magnetic Resonance Imaging (b)
showed a voluminous heterogeneous tumour occupying the left
liver. The injection of contrast showed a late vascularisation.
decided by the multidisciplinary Cancer Board. A followup
consisting in regular clinical consultations and CT-scan was
performed.Nosignofrecurrencewasremarkedat25-month
follow-up.
Case 2. A 15-year-old male, in a good overall health,
presented acute epigastric pain and an upper abdominal
palpable mass of recent appearances. The ultrasound and
the CT-scan revealed a voluminous heterogeneous tumour
of 15cm in the left liver which compressed the surrounding
structures (pancreas-stomach). Considering the high risk
of hemorrhagic rupture, a surgical resection was decided.
The surgical exploration showed a huge capsulated hepatic
tumour compressing the portal vein without signs of inﬁl-
tration of vascular structure. The tumour capsule presented
signs of spontaneous rupture without active bleeding. A
left hepatectomy (segments II-III-IV) was performed. There
were no postoperative complication, and the patient was
discharged at postoperative day 10. Because of capsule
rupture and risk of tumour seeding an adjuvant chemother-
apy consisting in 6 cycles of IVA (ifosfamide, vincristine,
actinomycin D) was proposed. At 30 months followup,
the CT-scan showed two recurrence nodules involving the
hepatic ligament and the peripancreatic region, measuring
6 and 7cm, respectively. No others metastatic lesions
were found. Chemotherapy consisting in 3 cycles of IVA
followed by 3 cycles of adriamicine-cisplatine allowed an
objective response, with mild reduction of the lesions to
4 and 5cm, respectively. Complementary resection of the
hepatic segment I and pancreaticoduodenectomy (PD) with
extended lymphadenectomy was performed. The histology
conﬁrmed the recurrence of a rhabdoid tumour without
lymphatic involvement. The patient underwent postoper-
ative radiotherapy (40Gy/20 fractions). At 43-month fol-
lowup a new recurrence involving the remnant liver and the
posterior bladder space was detected. A new chemotherapy
with etoposide (3 cycles) was applied, followed by surgical
exploration and resection of a voluminous retroperitoneal
recurrence associated with right colon resection. The patient
was discharged at postoperative day 15, but he died 1 month
later due to a progressive cardiac failure.
2.1. Pathological Findings. The surgical specimen measured,
respectively,17×15×8cm/weigh942g(Case1)and15×14×
14cm/weigh 1400g (Case 2). The macroscopic examination
revealed a solid whitish tumour, with necrotic and hem-
orrhagic areas. The microscopic study showed a lobulated
uniform aspect of ﬁbrotic septa and glandular formations.
Theneoplasticcellswereroundorfusiform,looselycohesive,
and were seen within a ﬁbromyxoid stroma. Ovular nucleus
and prominent nucleolus were observed. The number of
mitosis was moderate (maximum 8 at Gx400/10 ﬁelds).
The cytoplasm contained abundant eosinophilic inclusions,
which caused the nuclei to be located in eccentric locations,
giving the characteristic rhabdoid appearance (Figures 2(a)
and2(b)).ThecytoplasmstainedpositivewithPAS(periodic
acid-Schiﬀ) and was digested after diastase. Necrotic and
hemorrhagic foci were included within the neoplastic mass.
The immunohistochemical study was performed. The
antivimentin antibody labelled the cytoplasm of almost
neoplastic cells, including the cells with rhabdoid features.
The anti-EMA (Epithelial Membrane Antigen) antibody
diﬀusely marked the cellular cytoplasm with reinforcement
of tumoral cells membranes. C-kit antibody signiﬁcantly
marked the cytoplasm of most neoplastic cells. Conversely
the anti-PS-100, CK 22, CK 7, CK 19, CK 20, HMB45,
desmin, myogenin, caldesmon, CD34, BCL2, synaptophysin,
monoclonal NSE, and P53 antibodies did not remarkable
labelled the neoplastic cells.
The researches of speciﬁc genetic translocations for
Ewing tumour, alveolar rhabdomyosarcoma, synovial-
sarcoma, and myxoid chondrosarcoma were negatives.
Finally the immunohistochemistry demonstrated lack of
n u c l e a rI N I 1p r o t e i ne x p r e s s i o n .
3. Discussion
MRTwasﬁrstidentiﬁed inthekidney ofinfantsand children
andwasdescribedin1978asrhabdomyosarcomatoidvariant
ofWilms’tumor[1,5].However,becauseofthelackofultra-
structural or immunohistochemical evidence of myogenic
diﬀerentiation, the term rhabdoid was later adapted for these
neoplasms [6–8].
With the same morphologic and immunohistochem-
ical features, identical tumors have been reported in aHPB Surgery 3
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Figure 2: The microscopic analysis of the specimen (hemotoxylin,
Phloxine, and Safran coloration) with 200 × magniﬁcation (a) and
400 × magniﬁcation (b).
wide variety of sites including the nervous system, eye,
tongue, nasopharynx, neck, mediastinum, thymus, heart,
uterus, urinary bladder, vulva, skin, soft tissue, paraver-
tebral region, and gastrointestinal tract [5, 9]. Extrarenal
rhabdoid tumours, although histologically, clinically, and
ultrastructurallyresemblingrenalrhabdoid tumours,areless
consistent in presentation. For this particular reason, the
existence of extrarenal rhabdoid tumours of childhood as
a true clinicopathologic entity has been questioned. The
current consensus is that it is indeed a true but heterogenous
entity. As for extrarenal rhabdoid tumours in adults, some
of these tumours are identical to those seen in children,
whereas others have focal areas of rhabdoid diﬀerentiation
within an otherwise distinctly diﬀerentiated tumour such
as a carcinoma, sarcoma, or melanoma [5]. Rhabdoid
tumours characteristically are highly cellular neoplasms that
showsomewhatmonotonousnoncohesivetopoorlycohesive
sheets of large polyglonal cells with abundant eosinophilic
cytoplasm that may contain intracytoplasmic inclusions.
The nuclei are eccentric, hyperchromatic, vesicular and
pleomorphicandhaveprominentnucleoli.Ultrastructurally,
the most distinctive feature is the presence of cytoplasmic
ﬁlaments. These may be of variable diameters and are
arranged in bundles or whorls. The globular inclusions
seen by light microscopy are composed of parallel ﬁlaments
between 6 and 9nm in diameter, packed in concentric
whorls that often have lipid droplets or mitochondria at
the center [5, 9]. Imunohistochemically, the rhabdoid cells
express both cytokeratin and vimentin and lack myogenic
diﬀerentiation [5, 6, 10]. Recent studies show that rhabdoid
diﬀerentiation represents a clonal evolution in tumours of
diﬀering histogenesis. Cytogenic studies have shown that
classic rhabdoid tumours contain a characteristic chromo-
somal abnormality involving chromosome 22, leading to
mutation of Hsnf5/INII gene, located on chromosomal
band 22q11.2, with lack of expression on INI1 protein at
immunohistochemistry [6, 10–14]. Such a way a genetic
diagnosis is possible [15].
In summary, primary malignant rhabdoid tumours of
various organs have been described in literature. Only rare
cases are seen in the gastrointestinal tract, in particular,
the liver. These poorly diﬀerentiated neoplasms may pose
a great deal of diﬃculty in the diagnosis because there is
no glandular, squamous, or any other diﬀerentiation. In
addition, it is almost impossible to make the distinction
whether the tumour is of primary origin or represents a
metastasis from rhabdoid tumour of a diﬀerent site. In the
two cases no other extrahepatic lesions were found at pre-
operative imaging studies and surgical exploration.
Liver rhabdoid tumour is a rare histological ﬁnding
especially in young adults. In a review article published
in 2004, Yuri et al. [4] found 19 cases with a median
age of diagnosis of 16,7 months. Moreover nearly all
cases (89%) occurred in the ﬁrst 2 years of life, with no
gender diﬀerence. Although one report showed a 6-year
survival [16], the outcome of the other published cases was
uniformly fatal, despite aggressive treatment. The overall
mortality rate was 89% with a mean survival of 15.3 weeks.
Furthermore Tekautz et al. [17] analysed a population of 31
patients aﬀected by teratoid/rhabdoid tumours of the central
nervous system (CNS). They noticed a better response to
chemotherapy, a better two-years event-free survival (EFS)
and overall-free survival (OS) for patient 3 years or older,
compared to patients younger than 3 years (EFS 78% ± 14%
versus 11% ± 6%) (OS 89% ± 11 versus 17% ± 8). In our
study we reported a followup of 25 months without signs of
recurrence for Case 1.C a s e2 had a disease free survival of 31
months and an overall survival of 48 months. Probably a less
aggressive behaviour of MRT in later presentation compared
to infant could be supposed.
As concern chemoradiotherapy, no consistently eﬀective
regimen has yet been established. Ifosfamide, vincristine,
cyclophosfamide, etoposide, epirubicin and actinomycin D
based chemotherapies are the treatments of choice. Banzai
et al. [18]r e p o r t e da ne ﬀective response to combination
of ifosfamide-epirubicin-cisplatine for MRT of the ovary.
Tekautz et al. [17] described a regimen of high-dose
alkylator-based chemotherapy associated to radiotherapy,
followed by autologous bone marrow transplantation for
MRT of CNS. Satisfactory results were achieved in patients
3 years and older. However a common consensus was not
reached, and a standard regimen is not yet established. In
Case2,anassociationofsurgeryandchemoradiotherapywas
performed. This aggressive attitude permitted an acceptable
control of the recurrence disease with 48-month survival.
The aggressive and incurable nature of rhabdoid tumors
corroborates the need to develop a targeted and eﬀective4 HPB Surgery
therapy for these tumors. Rhabdoid tumors and cells are
exquisitely dependent on cyclin D1 for genesis and survival,
suggesting that targeting the cyclin/cyclin-dependent kinase
(cdk) axis may be an eﬀective therapeutic strategy for these
tumors. Currently, there are several studies regarding the
use of a pan-cdk inhibitor, ﬂavopiridol, that both inhibits
cdk activity and transcriptionally down-modulates cyclin
D1 which may eﬀectively inhibit rhabdoid tumor growth.
Flavopiridol is potentially a novel chemiotherapeutic agent
for rhabdoid tumors [19].
In conclusion MRTs are rare liver tumours. Histological
diagnosis is not always easily achieved, but lack of expression
on INI1 protein at immunohistochemistry could be helpful.
Usually liver rhabdoid tumours developed in pediatric
patients and in most of the cases the prognosis is very
poor. Presentation in young adults is exceptional, and they
probably have a better biological behaviour. As concern
chemoradiotherapy no consistently eﬀective regimen has yet
been established. Aggressive surgical conduct seems justiﬁed
also in case of recurrence disease.
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